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Background: Carcinoid tumor with consecutive endocardial fibroelastosis of the right heart, known as carcinoid
heart valve disease (CHVD) or Hedinger’s syndrome, is accompanied by combined right-sided valvular dysfunction
with regurgitation and stenosis of the affected valves. Cardiac surgery with replacement of the tricuspid and/or
pulmonary valve is an established therapeutic option for patients with Hedinger’s syndrome. Little is known about
the long term outcome and the choice of prosthesis for the pulmonal position is still a matter of debate.
Methods: The authors report three cases of pulmonary valve replacement with stentless bioprostheses (Medtronic
Freestyle®, Medtronic PLC, Minneapolis, MN, USA) due to severe pulmonary valve degeneration in consequence of
Hedinger’s syndrome.
Results: All patients presented with re-stenosis of the pulmonal valve conduit at the height of the anastomoses in
a premature fashion. Due to the increased risk for repeat surgical valve replacement, two patients were treated by
transcatheter heart valves.
Conclusion: We do not recommend the replacement of the pulmonary valve with stentless bioprostheses in
patients with CHVD. These valves presented with an extreme premature degeneration and consecutive re-stenosis
and heart failure.
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The carcinoid syndrome with consecutive endocardial
fibroelastosis of the right heart was first described by
Christoph Hedinger as a “Metastatizing Carcinoid with
tricuspid valve degeneration and stenosis of the pulmo-
nal valve-(a new syndrome)” in 1954 [1]. Carcinoid tu-
mors have an incidence of 1.2 to 2.1 per 100,000 persons
and are characterized by flush, diarrhea and acute
asthma attacks [2,3]. The tumor releases vasoactive sub-
stances such as serotonin in the portal circulation, which
can be deactivated through the liver. When liver metas-
tases appear serotonin is secreted in the systemic circu-
lation and carcinoid heart and valve disease (CHVD)
known as Hedinger’s syndrome occur [4]. Replacement* Correspondence: and.schaefer@uke.de
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unless otherwise stated.of the tricuspid and pulmonary valve is a well established
and a feasible therapeutic option for these patients [5].
Nevertheless little is known in terms of long term out-
come and the choice of the valve prosthesis is still a
matter of debate. Here we report three cases of pulmon-
ary valve replacement with the Medtronic Freestyle®
(Medtronic PLC, Minneapolis, MN, USA) stentless bio-
prosthesis in patients with CHVD. All three of these pa-
tients presented with pulmonary valve degeneration and
were also treated with concomitant tricuspid valve re-
placement due to severe tricuspid valve insufficiency.Methods
Case 1
A 34-year-old male patient was transferred to our institu-
tion in June 2011 with cyanosis and new diagnosed severe
pulmonary valve stenosis (PS) and a severe tricuspid valve
insufficiency (TI). The patient suffered from asthma,l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ography (TTE) revealed a normal left-ventricular (LV)
function and a mildly reduced right-ventricular (RV) func-
tion. The transvalvular gradient of the pulmonary valve
was elevated up to 59/19 mmHg (peak/mean) with con-
comitant severe insufficiency due to shortened and thick-
ened leaflets. The tricuspid valve also showed severe
insufficiency. The systolic pulmonary artery pressure
(sPAP) was 43 mmHg. Pulmonary embolism could be
ruled out by right heart catheter. Abdominal CT pre-
sented a tumor in the midgut and metastases of the liver.
Biopsy specimen of the liver confirmed the clinical diag-
nosis of a CHVD. In August 2011 the patient underwent
cardiac surgery. The pulmonary valve was replaced with a
Medtronic Freestyle® (25 mm) and the tricuspid valve with
an Edwards Perimount® (31 mm) pericardial valve. Add-
itionally a patch plasty of the pulmonal artery bifurcation
was performed to avoid distal stenosis of the pulmonary
conduit. Detailed procedural data are summarized in
Table 1. At time of discharge the TTE presented trace TI
and trace PI with a transprothetic gradient of 14/5 mmHg
(peak/mean). Sandostatin therapy was induced. In January
2012 resection of the midgut tumor and partial resection
of liver metastasis was done. The patient was admitted
again to our centre in June 2012 for transarterial che-
moembolization (TACE) of the residual liver metastasis.
At time of admission the patient presented with cardiac
decompensation due to a severe re-stenosis of the pul-
monary valve conduit with a pressure gradient of 90/
48 mmHg. The tricuspid valve bioprosthesis presented a
regular function. After an uncomplicated TACE proced-
ure, a balloon-valvuloplasty of the pulmonary valve con-
duit was performed with a postprocedural decrease of the
peak pressure gradient to 30 mmHg. In June 2013 the pa-
tient was referred to our centre with relapse of right heart
failure. The TTE now revealed a transprosthetic peak
pressure gradient of the pulmonary valve conduit of
80 mmHg (Figure 1A). Angiography of the right heart pre-
sented a regular function of the valve itself, but stenosis of
the proximal conduit-anastomosis with a diameter of
12 mm and stenosis of the distal conduit-to-pulmonalTable 1 Procedural data*
Patient 1
Pulmonal valve replacement Medtronic Freestyle 25 mm
Tricuspid valve replacement Edwards Perimount 31 mm
Concomitant procedure Patch plasty of the pulmonal
artery bifurcation
Operation time (min) 240
Cross clamp time (min) 102
CPB time (min) 161
CPB- cardiopulmonal bypass, Min- minutes.
*All surgical procedures were performed with support of ECC via bicaval and aorticartery anastomosis with a diameter of 11.8 mm (Fig-
ure 1B). A successful balloon dilation of the distal stenosis
was performed followed by a staged percutaneous, trans-
venous stent implantation into the pulmonary artery and
subsequent implantation of a balloon-expandable trans-
catheter heart valve in September 2013. At 6 month follow
up echo presented a regular function of the pulmonal
valve.
Case 2
A 58-year-old female patient was transferred to our in-
stitution as emergency admission in January 2011 with
congestive heart failure (New York Heart Association
[NYHA] Class II) and peripheral edema. Besides the pa-
tient suffered from breast cancer and was treated with
two complete cycles of adjuvant chemotherapy. The
TTE revealed a mildly reduced LV and RV function with
a severe tricuspid valve insufficiency and a moderate
stenosis. The pulmonary valve showed a moderate insuf-
ficiency with a pressure gradient of 14/5 mmHg. In May
2011 carcinoma tumor of the midgut and multiple liver
metastases could be verified by MRT and liver biopsy. In
June 2011 colon-, ovar- and cholecystektomy were per-
formed without complications. Sandostatin therapy was
induced. The patient was transferred as emergency ad-
mission to our institution again in September 2011 due
to relapsed cardiac decompensation with ascites and se-
vere dyspnea (NYHA III-IV). The pulmonary valve now
presented with a pressure gradient of 18/9 mmHg. In
February 2012 pulmonary valve replacement with a
Medtronic Freestyle® (25 mm) and tricuspid valve re-
placement with an Edwards Perimount® (29 mm) was
performed. Additionally a patch plasty of the pulmonal
artery bifurcation was done. At time of discharge tricus-
pid and pulmonary bioprostheses presented with a trace
insufficiency. In April 2013 the patient presented again
with heart failure symptoms. The TTE presented a regu-
lar function of the tricuspid bioprosthesis. The conduit
of the pulmonary valve was severely stenotic with a con-
secutive pressure gradient of 57/34 mmHg (Figure 2A).
Right heart catheter exposed a stenosis of the proximalPatient 2 Patient 3
Medtronic Freestyle 25 mm Medtronic Freestyle 25 mm
Edwards Perimount 29 mm Edwards Perimount 25 mm
Patch plasty of the pulmonal
artery bifurcation






Figure 1 Transthoracic echocardiography and angiography of patient no. 1. A: Transthoracic echocardiography of the degenerated
pulmonal valve prosthesis in doppler color flow with signs of stenosis. B: Angiography with stenosis of the proximal and distal anastomoses
(see markers) of the bioprosthesis.
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and the distal conduit- anastomosis showed no significant
stenosis (Figure 2B). In September 2013 transvenous inter-
ventional valve-in-valve procedure was performed as de-
scribed in case 1. At 6 month follow up newly occurred
metastases of the ovar were found. The pulmonal valve
showed a regular function.
Case 3
A 51-year-old female patient was transferred to our in-
stitution in May 2011 with a known carcinoid tumor,
progressive dyspnea (NYHA III) and progressive periph-
eral edema for the last two years. The neuroendocrine
tumor of the ileum was first diagnosed in 2008. Midgut
resection was performed in 2008 and liver metastases
were verified by CT. Sandostatin therapy was induced
postoperatively. Significant coronary artery disease re-
quiring intervention was ruled out by angiography. The
TTE revealed a severe tricuspid valve insufficiency and a
pressure gradient of the pulmonary valve of 13/8 mmHg.
Diagnosis of Hedinger’s syndrome was confirmed and
tricuspid valve replacement was performed in June 2011Figure 2 Transthoracic echocardiography and angiography of patient
pulmonal valve prosthesis in continuous wave doppler with signs of steno
anastomosis (see marker).with a Medtronic Hancock® (27 mm). At time of dis-
charge the tricuspid bioprosthesis presented a regular
function and clinical condition showed significant im-
provement with dyspnea NYHA I and no peripheral
edema. In September 2011 the patient was transferred
again to our institution due to recurrence of dyspnea
and peripheral edema. The TTE presented a regular
function of the tricuspid valve bioprosthesis but a severe
insufficiency and a moderate stenosis of the pulmonary
valve with a pressure gradient of 23/12 mmHg. After
recompensation the patient could be discharged. In June
2012 the patient presented again with right heart failure.
Leading clinical symptoms were dyspnea, peripheral edema
and additionally severe ascites. The echo now revealed a
moderate insufficiency of the tricuspid valve bioprosthesis
and the pulmonary valve was severely insufficient and
moderately stenotic. The right heart function was reduced
(Tricuspid annular plane systolic excursion [TAPSE] of
8 mm). Implantation of a Medtronic Melody® valve
through right heart catheter was terminated due to a rather
small annulus diameter of the pulmonary valve (23 mm).
In December 2012 re-tricuspid valve replacement andno. 2. A: Transthoracic echocardiography of the degenerated
sis. B: Angiography of the bioprosthesis with stenosis of the proximal
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tively no early degeneration of the tricuspid valve was seen.
The insufficiency was a result of a compromised leaflet due
to a papillary muscle. The pulmonary valve was replaced
with a Medtronic Freestyle® 25 mm. Additionally a patch
plasty of the pulmonary artery bifurcation was done to
avoid stenosis of the distal anastomosis. The postoperative
echo showed a regular function of both prostheses. Unfor-
tunately the patient died in January 2013 due to a compli-
cation during TACE procedure. Computed tomography
10 days prior to the TACE procedure presented a stenotic
distal anastomosis of the pulmonary valve conduit with a
diameter of 14.8 mm (Figure 3).
Consent
Written informed consent was obtained from the pa-
tient’s guardian/parent/next of kin for the publication of
this report and any accompanying images.
Results
Here we reported three cases of pulmonary valve re-
placement with stentless bioprostheses (Medtronic Free-
style®) in patients suffering from CHVD. All patients
presented with re-stenosis at the height of the anasto-
moses of the valve conduit in a premature fashion.
Hence, the re-stenosis, although clinically remarkable,
was not a problem of the valve itself. Due to the in-
creased risk for repeat surgical valve replacement, two
patients were treated by percutaneous stent implantation
into the pulmonary artery, followed by the implantation
of a balloon-expandable transcatheter heart valve.Figure 3 Computed tomography of the thorax with stenosis of
the distal anastomosis of the pulmonary valve conduit with a
diameter of 14.8 mm.Discussion
CHVD almost exclusively affects right-sided heart valves,
since circulating serotonin is metabolized by pulmonary
endothelial cells, thus sparing left-sided valves. Although
the pathophysiology of CHVD is not fully understood,
certain distinct features of this entity have been well rec-
ognized. The deposition of carcinoid fibrotic tissue usu-
ally begins on the downstream aspect - that is, the
ventricular aspect of the tricuspid. valve and the arterial
aspect of the pulmonary valve -leading to a thickening of
valvular tissue with the subsequent restriction of leaflet
motion. The final stage is a combined valvular dysfunc-
tion with regurgitation and stenosis of the affected valves
[6]. Surgical valve replacement is usually necessary in
advanced stages of the disease. Whether biological valve
substitutes are subject to a continuous degenerative
process is not entirely clear at present due to the rarity
of the disease and inconclusive findings in the current
literature [7].
Despite that, replacement of degenerated heart valves
due to Hedinger’s syndrome is an established therapeutic
option [5]. Especially replacement of the tricuspid valve
with a stented bioprosthesis seems to offer an acceptable
lifespan with no early valve deterioration and is sup-
ported by the above mentioned clinical and surgical
cases [7]. In contrast the appropriate valve type for pul-
monary valve replacement is still a matter of debate.
Voigt et. al suggested a stentless bioprosthesis for the pul-
monary valve position to avoid anticoagulation prior to
hepatic de-arterialization [8]. Contrary to that Mokhlesa
and colleagues showed that mechanical valve prostheses
are not accompanied by valve related complications such
as bleeding or thrombosis [9].
In the presented cases we performed pulmonary valve
replacement with stentless bioprostheses and a concomi-
tant patch plasty, which is compellent at the time of re-
placement. The patch plasty was used to increase the
RVOT to pulmonary valve annulus continuum. The idea
was to implant valves greater in diameter and avoid at
least a re-stenosis involving the pulmonary artery. This
principle could not be proved in our case series since re-
stenosis of the anastomoses occurred in all our patients
regardless of the performed patch plasty. In two of the
described cases our patients required interventional
treatment due to stenotic lesions involving the anasto-
moses of the valve replacement. Extreme premature de-
generation within 1.5-2 years after implantation should
be avoided due to consecutive recurrence of heart failure
and mortality, respectively.
The two patients who were treated by percutaneous
stent implantation into the pulmonary artery, followed
by the implantation of a balloon-expandable transcathe-
ter heart valve presented a favorable acute outcome, with
adequate valve function and no paravalvular leakage as
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ents were elevated in both cases. The patients had an
uneventful postoperative course and were discharged
home in timely fashion. Both patients showed a normal
ejection fraction of the right ventricle in the 6 month
follow-up.Conlusions
We can not recommend the replacement of the pulmon-
ary valve with stentless bioprostheses in patients with
CHVD. Maybe stented bioprostheses or mechanical pros-
theses with no anastomoses with foreign material have the
potential to avoid re-stenosis. The short durability of
stentless bioprostheses and therefore the higher incidence
of redo-surgery or intervention, which was shown in our
cases, led us to the strong conviction to not utilize stent-
less bioprostheses in pulmonal position in patients with
CHVD, prospectively.
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